Solassol, I.; Pinguet, F.; Quantin, X.
FDA- and EMA-Approved Tyrosine Kinase Inhibitors in Advanced EGFR-Mutated Non-Small Cell Lung Cancer: Safety, Tolerability, Plasma Concentration Monitoring, and Management. Biomolecules 2019, 9, 668.
https://doi.org/10.3390/biom9110668
AMA Style
Solassol I, Pinguet F, Quantin X.
FDA- and EMA-Approved Tyrosine Kinase Inhibitors in Advanced EGFR-Mutated Non-Small Cell Lung Cancer: Safety, Tolerability, Plasma Concentration Monitoring, and Management. Biomolecules. 2019; 9(11):668.
https://doi.org/10.3390/biom9110668
Chicago/Turabian Style
Solassol, Isabelle, Frédéric Pinguet, and Xavier Quantin.
2019. "FDA- and EMA-Approved Tyrosine Kinase Inhibitors in Advanced EGFR-Mutated Non-Small Cell Lung Cancer: Safety, Tolerability, Plasma Concentration Monitoring, and Management" Biomolecules 9, no. 11: 668.
https://doi.org/10.3390/biom9110668
APA Style
Solassol, I., Pinguet, F., & Quantin, X.
(2019). FDA- and EMA-Approved Tyrosine Kinase Inhibitors in Advanced EGFR-Mutated Non-Small Cell Lung Cancer: Safety, Tolerability, Plasma Concentration Monitoring, and Management. Biomolecules, 9(11), 668.
https://doi.org/10.3390/biom9110668